Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30069139 | 1.00 | HSD17B10 (0.45) | HSD17B10ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL28829166 | 1.00 | HSD17B10 (0.45) | HSD17B10ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL30341139 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30341137 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30876511 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29199944 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29135004 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29199941 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29135000 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29181926 | 0.88 | HSD17B10 (0.45) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-01-31 | — | — | US | disclosed |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021124172-A1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566022-B2 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, ZFX, HBG1 | HSD17B10 1799/4885ALDH1A1 715/4885POLB 689/4885 |
| US-20220402904-A1 | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, ZFX, HBG1 | HSD17B10 1867/4885ALDH1A1 700/4885POLB 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.